MODIFICATION
A -- Science and Technology Platforms Applied to Medical Countermeasure (MCM) Development - Pre-Proposal Conference (7/16/12) slide show presentation
- Notice Date
- 7/20/2012
- Notice Type
- Modification/Amendment
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, Office of the Secretary, Acquisitions Management, Contracts, & Grants (AMCG), Office of the Assistant Secretary for Preparedness & Response (ASPR), Department of Health and Human Services, 330 Independence Ave. SW, G640, Washington, District of Columbia, 20201, United States
- ZIP Code
- 20201
- Solicitation Number
- BARDA-BAA-12-100-SOL-00013
- Point of Contact
- Carolyn Keeseman, Phone: 202-260-0950, Elizabeth Steiner, Phone: 2022058926
- E-Mail Address
-
carolyn.keeseman@hhs.gov, elizabeth.steiner@hhs.gov
(carolyn.keeseman@hhs.gov, elizabeth.steiner@hhs.gov)
- Small Business Set-Aside
- N/A
- Description
- Presentation slides from Multi-BAA Pre-Proposal Conference July 16, 2012, Washington DC. The presentation slides from Multi-BAA Pre-Proposal Conference which was held on July 16, 2012 in Washington DC are included as an attachment to this solicitation. The mission of the Biomedical Advanced Research and Development Authority (BARDA) is to develop and procure medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases. Specifically, BARDA supports the advanced development and procurement of drugs, vaccines and other products that are considered priorities for national health security. BARDA funding bridges the "valley of death" characterizing the late stages of product development. BARDA's support ensures continuity of funding at a critical point for medical countermeasures developed by industry or emerging from the basic research and preclinical development activities sponsored by the National Institutes of Health (NIH). In procuring medical countermeasures for the Strategic National Stockpile, BARDA enhances the capabilities of the Centers for Disease Control and Prevention (CDC) to organize an effective response. The Pandemic and All Hazard Preparedness Act (PAHPA) directs BARDA to promote (i) innovations in technologies that may assist countermeasure and product advanced research and development, (ii) research on and development of research tools and other devices and technologies, and (iii) research to promote strategic initiatives. The 2011 BARDA Strategic Plan defines BARDA's vision and lays out a series of capability goals over a five year period (2011-2016). Amongst BARDA's guiding principles is supporting the development of novel platform technologies that provide flexible systems for the production of medical countermeasures against a variety of threats. Through this Broad Agency Announcement (BAA), BARDA seeks to address, in part, BARDA's Goal 4, responsive and nimble programs and capabilities to address novel and emerging threats, as well as support the technological and scientific advancements of medical countermeasures for biodefense and pandemic influenza. The PAHPA and BARDA Strategic Plan are located on the ASPR website: http://www.phe.gov/Preparedness/legal/pahpa/pages/default.aspx and http://www.phe.gov/about/barda/Pages/2011barda-stratplan.aspx. This Broad Agency Announcement (BAA) is a continuation of a previous BAA (BARDA-BAA-11-100-SOL-00001) and is similarly designed to promote science and technology advancements of platforms applied to MCM development for the Strategic Science and Technology Division (SST) of BARDA. The Government's intent is to solicit potential advancements in science and technology in the following BARDA SST Areas of Interest: 1.Pipeline acceleration and evaluation of candidate vaccines and therapeutics. 2.Product improvements to enhance safety, efficacy, ease of use, and manufacturability of MCM. 3.Product repurposing to treat novel and emerging pathogens. 4.In vitro diagnostic platforms for the rapid diagnosis of human infection. The specific application of the technologies will focus on biodefense, pandemic influenza, and other emerging infectious diseases (EID). BARDA is open to evaluation of technologies at multiple stages of development, but advanced development activities of products specific for CBRN and Influenza will not be considered. Development activities are to be fully integrated with regulatory activities associated with product development efforts. BARDA anticipates awarding multiple contracts and/or other transactions for research and development efforts from this BAA that have sufficient potential for success, are of interest to the Government, and support one or more of the listed BARDA SST Areas of Interest. Contact Information: Comments to this announcement, referencing synopsis BARDA-BAA-12-100-SOL-00013 may be submitted to SST-BAA@hhs.gov. Pre-proposal Conference: The presentation slide show from Multi-BAA Pre-Proposal Conference (which was held on July 16, 2012 in Washington DC) is included as an attachment to this solicitation. Contracting Office Address: Office of the Assistant Secretary for Preparedness & Response (ASPR) Department of Health and Human Services 330 Independence Ave. SW G640 Washington, District of Columbia 20201 United States Please contact the Contracting Officer for additional information. Point of Contact(s): Carolyn Keeseman, Contracting Officer Phone: 202-260-0950 Fax: 202-205-6061 Email: Carolyn.Keeseman@hhs.gov Elizabeth Steiner, Contract Specialist Phone: 202-205-8926 Fax: 202-205-6061 Email: Elizabeth.Elmazahi@hhs.gov
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/OOS/OASPHEP/BARDA-BAA-12-100-SOL-00013/listing.html)
- Record
- SN02810048-W 20120722/120720235037-2ab2570e8cfe5d0a2601f2e5e007340c (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |